Chicago—A string of controversies in recent years over pharmaceutical companies withholding information about drug risks and researchers failing to disclose financial ties with drug companies has shaken the confidence of clinicians and patients alike. Last year, officials questioned whether data indicating that certain drugs (such as Merck & Co’s pain relief drug rofecoxib and GlaxoSmithKline’s paroxetine, an antidepressant) pose risks for patients were known by the companies but not reported, events that highlighted the need for greater transparency in drug trials.
Hampton T. Biomedical Journals Probe Peer Review. JAMA. 2005;294(18):2287–2288. doi:https://doi.org/10.1001/jama.294.18.2287
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: